Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFT1946 in BRAF-V600 Mutant Solid Tumors
2022-501618-70-00Phase 2Completed
- Sponsor
- C4 Therapeutics
- Start
- Jun 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of tagarafdeg in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 2 more (5 arms), sponsored by C4 Therapeutics. Primary endpoints: Incidence of dose limiting toxicities, Frequency and severity of Adverse Events and Serious Adverse Events and 4 more. Started Jun 2023; status: completed.
02
Drugs
tagarafdeg
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on 2022-501618-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501618-70-00.